Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene reported strong clinical progress in the March 2026 quarter, highlighted by positive Phase 1b results for its lead CAR T therapy azer-cel in CAR T-naive patients. The trial showed a 100% overall response rate in CLL/SLL and 80% in MZL, and its multi-indication basket design is intended to broaden potential registration pathways and focus resources on the most promising indications.
The company has amended the Phase 1b protocol to add a BTKi combination arm and include Mantle Cell Lymphoma as a new indication, signalling an expansion of azer-cel’s potential market. Operationally, Imugene strengthened its balance sheet with a A$2.74 million R&D tax refund and a $16 million capital raising, while the selection of azer-cel data for an oral presentation at ASCO 2026 enhances its scientific visibility and could support future partnering or commercialization prospects.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a Sydney-based clinical-stage immuno-oncology company focused on developing novel therapies for cancer. Its primary program is azer-cel, an allogeneic off-the-shelf CD19 CAR T cell therapy targeting blood cancers including diffuse large B-cell lymphoma and other CD19-positive B-cell malignancies, with trials underway across multiple sites in the U.S. and Australia.
Average Trading Volume: 1,591,716
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$48.37M
Learn more about IMU stock on TipRanks’ Stock Analysis page.